Detalhe da pesquisa
1.
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer.
Breast Cancer Res Treat
; 188(2): 369-377, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34125340
2.
Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.
Ann Hematol
; 98(5): 1217-1224, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30824956
3.
A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab.
Br J Clin Pharmacol
; 84(10): 2336-2343, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29926514
4.
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
JAMA
; 317(1): 37-47, 2017 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27918780
5.
Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial.
Breast
; 58: 18-26, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33892316
6.
A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim.
J Cancer Res Clin Oncol
; 144(6): 1087-1095, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29671069
7.
Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer.
Clin Lung Cancer
; 16(3): 200-8, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25516338
8.
An exploratory subgroup analysis of race and gender in squamous cancer of the head and neck: inferior outcomes for African American males in the LORHAN database.
Oral Oncol
; 50(6): 605-10, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24637172
9.
Pemetrexed in head and neck cancer: a systematic review.
Oral Oncol
; 49(6): 492-501, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23466170
10.
Prospective observational comparison of clinical outcomes between african-american and caucasian patients receiving second-line treatment with pemetrexed for advanced non-small-cell lung cancer.
Clin Lung Cancer
; 14(6): 726-35, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23910068
11.
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
J Clin Oncol
; 31(34): 4349-57, 2013 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24145346
12.
Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer.
Clin Lung Cancer
; 13(1): 24-30, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21831719
13.
Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Clin Lung Cancer
; 10(4): 252-6, 2009 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19632943
14.
Tratamiento médico de 44 pacientes con carcinoma del conducto anal / Medical treatment of 44 patients with anal canal carcinoma
Medicina (B.Aires)
; 55(3): 243-8, mayo-jun. 1995. tab
Artigo
em Espanhol
| LILACS | ID: lil-155117